A Randomised, Open-label Phase III Trial Evaluating the Addition of Denosumab to Standard First-line Anticancer Treatment in Advanced NSCLC
Phase of Trial: Phase III
Latest Information Update: 05 Jun 2017
At a glance
- Drugs Denosumab (Primary)
- Indications Bone metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms SPLENDOUR
- 07 Jun 2017 Biomarkers information updated
- 24 Apr 2017 Planned End Date changed from 1 Apr 2020 to 1 Sep 2020.
- 24 Apr 2017 Planned primary completion date changed from 1 Apr 2019 to 1 Sep 2019.